AI Accelerates the Future of Medicine Design

Key points

• AstraZeneca is using AI to speed up biologic drug discovery, cutting timelines and lifting productivity.
• McKinsey estimates AI combined with computational tools could shorten drug discovery timelines by up to 50%.
• AI is making once-unreachable disease targets viable for biologic treatment.
• AstraZeneca is building a facility in Kendall Square, Cambridge, Massachusetts where AI and robotic automation will run a continuous closed-loop discovery system.

Designing a new medicine is expensive and failure-prone. Most candidates never reach patients. The problem is sharpest for biologic medicines, therapies built from engineered proteins rather than synthetic chemistry, because scientists must comb through enormous numbers of possible molecules to find the rare few that bind correctly, stay stable in the body, and can be manufactured at scale.

AI is now central to that search. AstraZeneca has been expanding its engineering teams to push further into the field. "Everything we do, whether it's design, make, test, or analyze, is now computationally enhanced," says Puja Sapra, senior vice president and head of R&D biologics engineering and oncology targeted discovery at AstraZeneca. The company's approach follows a build-measure-learn loop: AI ranks candidate molecules, scientists focus lab time on the top picks, and the feedback cycle tightens. Fewer dead ends, faster iteration.

We covered the broader investment wave on 22 July, when the US government committed $5 billion to AI-driven drug discovery across fifteen federal agencies.

How is AI changing drug design?

AI isn't just compressing timelines. It's opening territory traditional methods couldn't reach. Where older biologics typically hit one disease pathway, a new generation can strike multiple targets at once or deliver treatments directly to specific cells. AI models help balance potency, stability, manufacturability and safety across all those variables simultaneously. "Drugging the undruggable is becoming a reality," Sapra says.

What role does data play?

McKinsey puts the potential timeline reduction at up to 50%, but every model is only as good as what it learned from. AstraZeneca's datasets are proprietary and multimodal, covering molecular structures, binding measurements, safety profiles and manufacturing outcomes. Failed experiments matter as much as successful ones: each one sharpens the next model. "Data is our differentiator," Sapra says. That's a real competitive moat, and it's one reason smaller players without years of proprietary experimental data will struggle to keep up.

What's next for AI in medicine?

The end goal is "de novo" design, building entirely new protein sequences from scratch to fit a desired drug profile, rather than modifying existing ones. Getting there needs richer standardised training data, solid evaluation benchmarks for AI-generated candidates, and teams fluent in both machine learning and biology.

Safety prediction is the hardest piece. "One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body," Sapra says. AstraZeneca is tackling it with advanced cell systems and micro-scale organ models paired with AI, effectively virtual clinical trials that generate biological signals without traditional testing bottlenecks.

For patients, the practical upside is shorter waits. If the timelines hold, diseases that currently have no viable treatment could move from lab concept to clinical candidate faster than any prior generation of drug research allowed.

Common questions

How does AI directly affect patients?

Faster discovery means treatments could reach patients sooner, and hitting previously "undruggable" targets means some diseases that currently have no good medicine may finally get one.

Should you worry that AI is running drug safety decisions?

No. Sapra is explicit that scientists stay central, providing oversight and strategic direction to ensure outputs are explainable and directed toward patient benefit. AI narrows the options; humans decide what gets pursued.

Can AI replace human scientists in drug discovery?

Not yet, and probably not soon. It handles data analysis and molecule ranking at a scale no human team could match, but judgement, ethics and experimental strategy remain squarely human responsibilities.